Wearable device tracks movement in people with amyotrophic lateral sclerosis
Tests a wearable Actimyo device that records movement in adults with ALS.
Plain-language title generated from the registry record
Registry title: Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.
Key facts
- Where
- Leuven and Liège, BelgiumSee the 2 sites
Where in Belgium
- Katholieke Universiteit LeuvenLeuven, BelgiumTaking people
- Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la CitadelleLiège, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Liege
- Trial code
- NCT06228001
- Record updated
- 19 May 2025
- Original description
ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS) may be included on a voluntary basis. The investigators plan to include a group of approximately 30 patients with ALS.Read full original descriptionShow less
Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.
ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS) may be included on a voluntary basis. The investigators plan to include a group of approximately 30 patients with ALS.
The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Inclusion: Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm; Over 18 years old; Signed informed consent; If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.
Exclusion: Any other previous or present pathology having an impact on motor function; Recent surgery or trauma (less than 6 months) in the upper or lower limbs; Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion; Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection; Patients participating in an interventional clinical trial.